Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multicenter, Vehicle-controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Multicenter, Vehicle-controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abametapir (Primary)
  • Indications Pediculosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Dr Reddys Laboratories; Hatchtech

    • Most Recent Events

    • 27 Jul 2020 According to a Dr Reddys Laboratories media release, the U.S. Food and Drug Administration (USFDA) has approved XEGLYZE (abametapir) lotion, 0.74% through a 505(b)(1) NDA.XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
    • 14 Sep 2015 According to a Dr. Reddys Laboratories media release dated 14 September 2015, Hatchtech has filed an NDA with the US FDA for Xeglyze (abametapir) lotion.
    • 18 Mar 2015 Results published in a Hatchtech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top